A Phase IV Study of the Antiviral Activity and Safety of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen in Korea.

Trial Profile

A Phase IV Study of the Antiviral Activity and Safety of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen in Korea.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2014

At a glance

  • Drugs Entecavir (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jan 2014 According to ClinicalTrials.gov record trials status changed from active, no longer recruiting to completed.
    • 08 Jun 2010 Planned end date changed from Dec 2013 to Aug 2013 as reported by ClinicalTrials.gov.
    • 04 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top